Ihr neues Infoportal.

Hepatitis D – Folge 2: Prävalenz in Österreich und Real World Data

Hepatitis D – Folge 1: Der Weg zur Diagnose und Behandlung

Eine Zusammenfassung der Covid-19 Therapiemöglichkeiten inklusive Veklury (Remdesivir) von Dr. Jürgen Prattes

COVID-19

Sacituzumab Govitecan: Toxizität und Management

Onkologie

Prof. Krause zu: COVID-19 assoziierte Murcomycose

FI Highlights 2021: Prof. Hönigl im Interview mit Österreichs Experten

Invasive Pilzerkrankungen

Prof. Schellongowski zu: Covid-19 assoziierte Candidiasis/Candidämien

FI Highlights 2021: Prof. Hönigl im Interview mit Österreichs Experten

Invasive Pilzerkrankungen

Prof. Willinger zu: Neonatale Candidämien

IFI Highlights 2021: Prof. Hönigl im Interview mit Österreichs Experten

Invasive Pilzerkrankungen

Dr. Salzer zu : Breakthrough Fungal Infections

FI Highlights 2021: Prof. Hönigl im Interview mit Österreichs Experten

Invasive Pilzerkrankungen

Prof. Lass-Flörl zu: IFI Diagnostics

FI Highlights 2021: Prof. Hönigl im Interview mit Österreichs Experten

Invasive Pilzerkrankungen

ÖGHO Mini-Satellitensymposium 04/2022

Volle Aufzeichnung mit Diskussion "„What`s New in Hematology in Terms of Invasive Fungal Infection”

Invasive Pilzerkrankungen

Sokal, M. E. et al: Safety and Efficacy of Sofosbuvir/Velpatasvir for the Treatment of Chronic Hepatitis C Infection in Children and Adolescents Aged 3 to 17 Years Old Through 24 Weeks Posttreatment

13.-16.11.2020 / AASLD

Lebererkrankungen

Riddler, S. et al: A Pooled Analysis of 8 Clinical Studies Suggests a Link Between Infl uenza-Like Adverse Events and Pharmacodynamics of the Toll-Like Receptor-7 Agonist Vesatolimod

23.-26.10.2022 / HIV Drug Therapy 2022

HIV

Orkin, C. et al: Outcomes After Switching From 144 Weeks of Blinded DTG/ABC/3TC or DTG+F/TAF to 96 Weeks of Open-label B/F/TAF

23.-26.10.2022 / HIV Drug Therapy 2022

HIV

Trottier, B. et al: Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) for the Treatment of People Living With HIV: 24-Month Analyses by Age, Race, Sex, Adherence and Late Diagnosis in a Multi-Country Cohort Study

23.-26.10.2022 / HIV Drug Therapy 2022

HIV

Robineau, O. et al: Risk Factors Associated With ≥ ±10% Weight Change in Treatment-Naïve and Treatment-Experienced People Living With HIV Initiating or Switching to an NNRTI- or INSTI-Based Antiretroviral Therapy in Four Large Cohort Studies

23.-26.10.2022 / AIDS 2022

HIV

Chastek, B. et al: ART Regimen Persistence Among Treatment-Experienced Patients With HIV Switching to aMTR or STR Since 2018

23.-26.10.2022 / HIV Drug Therapy 2022

HIV

Castagna. A. et al: Week 52 Subgroup Effi cacy Analyses of Long-Acting Subcutaneous Lenacapavir in Phase 2/3 in Heavily Treatment-Experienced People With Multidrug-Resistant HIV (CAPELLA Study)

23.-26.10.2022 / HIV Drug Therapy 2022

HIV

Antinori, A. et al: Common Adverse Events in Clinical Studies of People Using Lenacapavir for HIV Treatment

23.-26.10.2022 / HIV Drug Therapy 2022

HIV

Margot, N. et al: Phenotypic Analyses of Clinical Isolates With Capsid Substitutions Observed in People With HIV Treated With Lenacapavir

23.-26.10.2022 / HIV Drug Therapy 2022

HIV

Ramgopal, M. et al: 5-Year Outcomes of Bictegravir/Emtricitabine/Tenofovir Alafenamide as Initial Treatment of HIV-1 in Adults With High Baseline HIV-1 RNA and/or Low CD4 Count in Two Phase 3 Randomized Clinical Trials

23.-26.10.2022 / ID Week 2022

HIV